Compare Illinois Tool Works Inc. (ITW) vs 22nd Century Group Inc (XXII) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illinois Tool Works Inc. vs 22nd Century Group Inc — how do they compare? Illinois Tool Works Inc. trades at $264.13 (market cap $74.38B), while 22nd Century Group Inc trades at $0.81 (market cap $621.67K). The key difference: Illinois Tool Works Inc. is far larger — about 119645.5× 22nd Century Group Inc's market cap, and Illinois Tool Works Inc. pays a 2.63% dividend while 22nd Century Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Illinois Tool Works Inc. for 67 Days and 22nd Century Group Inc for 32 Days on average.
| ITW | XXII | |
|---|---|---|
Market Cap | $74.38B | $621.67K |
Volume | 1,125,477 | 45,625 |
Sector | Industrials | Consumer Staples |
52-Week High | $299.60 | $483.00 |
52-Week Low | $241.07 | $0.80 |
Typical Hold Time | 67 Days | 32 Days |
Enterprise Value | $83.23B | -$3.69M |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illinois Tool Works (ITW) trades at $264.71, up 1.36% on the day, with a bearish technical signal but strong fundamentals including a 19.39% net income margin and a 59-year dividend growth streak. Recent earnings have consistently beaten estimates, and the company raised its quarterly dividend to $1.72. Cash flow from operations remains robust at $3.13 billion for 2025, though net cash flow was slightly negative. The stock is near its consensus price target of $276.86, with support at $262 and resistance at $266.
ITW offers a stable investment with high profitability and consistent dividend growth, but faces headwinds from bearish technical indicators and mixed analyst sentiment. Upside is supported by operational efficiency and strong cash flow, while risks include economic sensitivity and high valuation multiples. The stock presents a balanced opportunity for income-focused investors seeking quality industrial exposure.
XXII trades at $0.8116, down 8.96% in the last session, with a bearish technical signal from moving averages. The company shows negative profitability metrics including -76.01% net income margin and -284.5% ROE, though valuation ratios appear low with P/S of 0.08 and P/B of 0.03. Recent news highlights regulatory progress in reduced-nicotine tobacco initiatives in France and Europe.
While analyst consensus is 75% buy with a $1,240 price target suggesting significant upside, fundamental challenges persist with consecutive earnings misses and negative cash flow from operations. The stock faces execution risk in commercializing its reduced-nicotine platform amid ongoing losses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illinois Tool Works Inc.
Illinois Tool Works is a diversified global manufacturer that produces specialized industrial equipment, consumables, and related services. The firm operates 87 global divisions through seven distinct operating segments: automotive OEM, construction products, food equipment, specialty products, test/measurement and electronics, polymers and fluids, and welding. About half of its revenue comes from its operations in North America, with the remainder originating from international markets. ITW takes a bottom-up and decentralized approach to portfolio management, with the exception that each segment must apply its 80/20 operating process modeled on the Pareto principle.
Read more on ITW →About 22nd Century Group Inc
22nd Century Group is a plant biotechnology company that uses genetic engineering and gene editing to control the levels of nicotine in tobacco plants. Its flagship product line, VLN®, is the first and only combustible cigarette authorized by the FDA as a Modified Risk Tobacco Product (MRTP), containing 95% less nicotine than traditional cigarettes to help adult smokers smoke less.
Read more on XXII →
